Efficacy and safety of Hyper-CVAD regimen for patients with adult acute lymphocytic leukemia

WANG Cheng-mei; CHEN Chen

doi:10.3760/cma.j.issn.1673-4777.2012.03.024

Abstract：Objective To evaluate the clinical efficacy and safety of Hyper-CVAD regimen for patients with adult acute lymphocytic leukemia.Methods A total of 66 cases with adult acute lymphocytic leukemia were divided into treatment group treated with Hyper-CVAD regimen(36 cases)and control group treated with traditional chemotherapy regimen(30 cases).The clinical efficacy and safety of the Hyper-CVAD regimen were observed.Results Compared with traditional chemotherapy,the complete response(CR) rate was significantly higher with Hyper-CVAD (P =0.03):CR was 86.1％ in treatment group and it was 63.3％ in control group.There was no evidence of significant association between CR rate in treatment group and gender,age,splenomegaly,hepatomegaly,lymphadenopathy,central nervous system involvement,leukocytosis,immunophenotype and karyotype.During follow-ups,overall 1-,2- and 3-year survival rates were 88.9％ ( 32 cases),80.6％ ( 29 cases) and 66.7％ ( 24 cases) in treatment group versus 73.3％ (22 cases),63.3％ ( 19 cases) and 46.7％ ( 14 cases) in control group.The estimated mean OS (over survival)time of patients in treatment group was 30.1 months (95 ％ CI:26.7-33.6 )and it was 23.6 months (95％ CI:24.5-30.2 ) in control group( P ＜ 0.05 ).The induction mortality rate and side effects showed no differences between treatment group and control group.Conclusions Hyper-CVAD regimen can be an optimistic therapy for patients with adult acute lymphocytic leukemia.Its side effects can be easily controlled.